Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,114 | 151 | 920 |
| Samples | 596 | 98 | 490 |
| Peptides | 421 | 70 | 355 |
Function
CDH5 · Cadherin 5
This gene encodes a classical cadherin of the cadherin superfamily. The encoded preproprotein is proteolytically processed to generate the mature glycoprotein. This calcium-dependent cell-cell adhesion molecule is comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Functioning as a classical cadherin by imparting to cells the ability to adhere in a homophilic manner, this protein plays a role in endothelial adherens junction assembly and maintenance. This gene is located in a gene cluster in a region on the long arm of chromosome 16 that is involved in loss of heterozygosity events in breast and prostate cancer. [provided by RefSeq, Nov 2015].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 408 amino-acid changes on canonical ENST00000341529 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CDH5 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CDH5 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Melanoma | 8/210 4% | 81/1899 4% |
| Hodgkins Lymphoma | 0/16 0% | 4/122 3% |
| Bladder Carcinoma | 4/58 7% | 23/956 2% |
| Endometrial Carcinoma | 2/42 5% | 15/612 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Colorectal Carcinoma | 17/143 12% | 69/3239 2% |
| Osteosarcoma | 4/45 9% | 1/166 1% |
| Other Solid Cancers | 3/94 3% | 34/1515 2% |
| Gastric Carcinoma | 3/74 4% | 32/1809 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 21/1390 2% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 13/810 2% |
| Cervical Carcinoma | 0/35 0% | 6/422 1% |
| Ovarian Carcinoma | 8/109 7% | 6/998 1% |
| Biliary Tract Carcinoma | 1/54 2% | 11/950 1% |
| Kidney Carcinoma | 0/85 0% | 23/1862 1% |
| Esophageal Carcinoma | 0/23 0% | 9/769 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Hepatocellular Carcinoma | 2/46 4% | 20/2210 1% |
| Head and Neck Carcinoma | 1/85 1% | 15/1574 1% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 20/2550 1% |
| Mesothelioma | 1/62 2% | 1/165 1% |
| Prostate Carcinoma | 4/13 31% | 14/2105 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Glioma | 5/52 10% | 11/2127 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 12/1592 1% |
| Plasma Cell Myeloma | 1/44 2% | 1/305 0% |
Mutation Distribution
Where CDH5 is mutated · all tissues, split by cell line vs tissue
How many mutations in CDH5 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,114 mutations in CDH5
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|